PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24503784-8 2014 CONCLUSIONS: The addition of dipeptidyl peptidase-4 inhibitor therapy with sitagliptin to the treatment regime of patients with type 2 diabetes mellitus and coronary artery disease is associated with a sustained improvement in myocardial performance during dobutamine stress and a reduction in postischemic stunning. Dobutamine 257-267 dipeptidyl peptidase 4 Homo sapiens 29-51 20075143-0 2010 DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Dobutamine 68-78 dipeptidyl peptidase 4 Homo sapiens 0-5 20075143-3 2010 We assessed the hypothesis that increasing the plasma concentration of GLP-1 by DPP-4 inhibition would protect the heart from ischemic left ventricular (LV) dysfunction during dobutamine stress echocardiography in patients with coronary artery disease. Dobutamine 176-186 dipeptidyl peptidase 4 Homo sapiens 80-85